Literature DB >> 17908354

Botulinum toxin as adjunctive therapy in refractory laryngeal granuloma.

E J Damrose1, J F Damrose.   

Abstract

OBJECTIVE: This study evaluated the role of botulinum toxin type A in the treatment of refractory laryngeal granulomas. STUDY DESIGN AND
SETTING: Retrospective clinical review at a tertiary care hospital. Seven patients with vocal process granulomas underwent percutaneous injection of botulinum toxin into both vocal folds, performed in an office setting. Total doses ranged from 10 to 25 U, divided between both vocal folds.
RESULTS: All patients experienced resolution of their granulomas over two to seven weeks. No patient developed aspiration pneumonia. All patients experienced hoarseness secondary to the injections, but voice quality returned to baseline in all patients as the toxin was degraded.
CONCLUSIONS: Botulinum toxin is safe and effective therapy in resolving vocal process granulomas in patients refractory to traditional therapy. The optimal treatment dose remains to be determined. SIGNIFICANCE: Percutaneous botulinum toxin injection is helpful in resolving laryngeal granulomas.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17908354     DOI: 10.1017/S0022215107000710

Source DB:  PubMed          Journal:  J Laryngol Otol        ISSN: 0022-2151            Impact factor:   1.469


  3 in total

1.  Surgery and proton pump inhibitors for treatment of vocal process granulomas.

Authors:  Duan Hong-Gang; Jin He-Juan; Zheng Chun-Quan; Fan Guo-Kang
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-05-16       Impact factor: 2.503

2.  Prognostic factors for prediction of follow-up outcome of contact granuloma.

Authors:  Young Ju Jin; Sun Joo Lee; Won Yong Lee; Woo-Jin Jeong; Soon-Hyun Ahn
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-02-08       Impact factor: 2.503

Review 3.  Diagnostic and therapeutic pitfalls in benign vocal fold diseases.

Authors:  Jörg Bohlender
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2013-12-13
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.